Infectious diseases have, over the last decade, been a relatively under-funded area of pharmaceutical research with ‘Big Pharma’ deprioritising
R&D in this space. But then an unprecedented global pandemic brought
about devastating human and economic damage, the impact of which will take a generation to overcome. For the pharmaceutical and biotech sectors, it has brought about extensive refocusing on infectious diseases, especially
for those with respiratory and inflammatory conditions.
AIM-quoted Poolbeg Pharma (POLB:AIM), a clinical stage, infectious disease
pharmaceutical company, is uniquely placed to target this substantial infectious disease market, which is expected to grow to $250 billion by 2025.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
